Introduction
============

Low grade inflammation localized in vascular tissue is increasingly recognized as an important contributor to the pathophysiology of hypertension ([@b13]), to the initiation and progression of atherosclerosis and the development of cardiovascular disease (CVD) ([@b60], [@b61]). Patients with CVD present increased expression and plasma concentrations of inflammatory markers and mediators ([@b7]; [@b67]). Among them, C-reactive protein (CRP) has been demonstrated as an independent risk factor for the development of hypertension ([@b8]; [@b72]), and has been associated with increased risk of diabetes ([@b6]) and CVD. Numerous epidemiological studies have shown that plasma levels of high-sensitivity CRP (hsCRP) are a powerful predictor of ischemic cardiovascular events in patients with stable or unstable angina. They appears to correlate with softer plaques that are more prone to rupture, and may even predict cardiovascular events among apparently healthy subjects ([@b57], [@b55]). Furthermore, hsCRP levels have been shown to correlate with systolic blood pressure (BP), pulse pressure, and incident hypertension ([@b10]). Thus CRP and high BP in combination have additional predictive value for cardiovascular outcomes, as they contribute as independent determinants of cardiovascular risk.

The activation of the renin-angiotensin system (RAS) is primarily involved in the pathophysiology of hypertension and the development of CVD ([@b66]). In addition to its effect on BP, angiotensin II is also a proinflammatory mediator ([@b33]; [@b48]). Antagonism of the RAS may improve cardiovascular outcomes beyond BP control, by reducing vascular inflammation and remodeling.

In this review we discuss the role of CRP as marker and/or mediator of low-grade inflammation in the vasculature of hypertensive patients and the potential advantages of antihypertensive medication that may attenuate the inflammatory mechanisms associated with hypertension.

RAS, inflammation, and hypertension
===================================

The activated components of the RAS play a key role in the pathophysiology of hypertension ([@b66]). Angiotensin II, one of the final products of the RAS, induces vascular remodeling and injury by several mechanisms. These include vasoconstriction, cell growth, generation of reactive oxygen species (ROS), and inflammation. Angiotensin II can induce inflammation within the vascular wall ([Figure 1](#fig1){ref-type="fig"}) and consequently trigger deposition of extracellular matrix, and hypertrophy and/or hyperplasia of vascular smooth muscle cells (VSMCs) ([@b76]) by modulating cytokine release ([@b63]) and pro-inflammatory transcription factors such as NF-κB ([@b24]), which in turn regulate adhesion molecule (VCAM-1 and ICAM-1) expression ([@b51]).
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Angiotensin II, aldosterone, as well as endothelin-1, can modulate basal superoxide production by activation of reduced nicotinamide adenine dinucleotide phosphate \[NAD(P)H\] oxidase and expression of its subunits ([@b39]). NAD(P)H oxidase is the major source of ROS in the vascular wall, and is expressed in endothelial cells, VSMCs, fibroblasts, and monocytes/macrophages ([@b21]; [@b74]) ([Figure 1](#fig1){ref-type="fig"}). ROS act as signaling molecules, but also in part by impairing endothelium-dependent vascular relaxation by reducing the bioavailability of nitric oxide (NO) ([@b54]; [@b28]). Vascular contractile responses are accordingly enhanced, associated with structural changes in the wall of small arteries and increased peripheral resistance ([@b79]). Increased ROS production induced by angiotensin II is involved in the mechanisms leading to vascular remodeling, through VSMC proliferation and hypertrophy and collagen deposition ([@b77]). ROS promote vascular inflammation ([@b74]) and exert effects on the development and progression of atherosclerosis ([@b29]). Angiotensin II-induced ROS production increases ICAM-1 expression, macrophage infiltration, macrophage/monocyte chemoattractant protein-1 (MCP-1) production, and vascular hypertrophy independently of BP elevation ([@b40]). Macrophages which infiltrate the adventitia or the media of blood vessels may generate oxidative stress by NAD(P)H oxidase, also in response to elevated BP ([@b64]). Mice deficient in monocytes/macrophages present less oxidative stress and less induction of inflammatory molecule upregulation by angiotensin II in the vasculature, and develop less endothelial dysfunction and vascular remodeling ([@b13]). This suggests a central role for macrophages and pro-inflammatory mediators in angiotensin II-induced vascular injury.

Angiotensin II is also involved in atherosclerotic lesion progression and plaque instability by stimulating the activation of MMPs (matrix metalloproteinases), which can digest the fibrous cap and thereby participate in the triggering of plaque rupture ([@b19]). In addition, angiotensin II stimulates the production of plasminogen activator inhibitor-I (PAI-1) ([@b80]), which may contribute not only to the prothrombotic state but also to plaque rupture in atherosclerotic lesions.

C-reactive protein as biomarker and mediator of inflammation
============================================================

CRP is a pentameric protein produced mainly by hepatocytes under the control of interleukin-6 as part of the non-specific acute-phase response to tissue damage, infection, inflammation and malignant neoplasia ([@b49]). Recent findings have documented that CRP is also produced by vascular smooth muscle cells and endothelial cells, and in human atheroma ([@b88]; [@b81]). Increased levels of serum CRP, particularly sensed by high sensitivity assay, are generally regarded as a humoral sign of inflammation, and may identify subjects at moderate or high risk of cardiovascular disease. hsCRP has been related to insulin resistance, systolic BP, pulse pressure and hypertension ([@b10]; [@b15]). hsCRP correlates with plasma levels of von Willebrand factor (vWF), tissue plasminogen activator, and cellular fibronectin, which are markers of endothelial dysfunction ([@b90]). Numerous epidemiological studies have shown that plasma hsCRP level is a powerful predictor of ischemic cardiovascular events in patients with stable or unstable angina, appears to be positively associated with softer plaques that are more prone to rupture ([@b41]), may even predict cardiovascular events among apparently healthy subjects ([@b57], [@b41]), and may be useful in targeting medium-risk patients who could benefit from aggressive cardiovascular preventative therapy.

Vascular inflammation of large arteries exerts its effects in part by impairing artery elasticity and increasing vascular stiffness, in the presence or absence of hypertension. A correlation between CRP and measures of arterial wave reflection and stiffness in asymptomatic subjects was recently demonstrated ([@b38]). CRP levels were also associated with the future development of hypertension independently of baseline BP ([@b67]; [@b12]), although this issue has been recently challenged ([@b43]). In the Women's Health Study which included over 15,000 women, after adjustment for the effects of other cardiovascular risk factors, high levels of CRP appeared to be predictive of cardiovascular events either in the absence or presence of high BP. In the latter case the risk was three-fold higher to that in the low CRP/low BP group ([@b8]). However, after adjustment for confounding factors, elevated CRP levels appear not to lead to elevated BP ([@b68]). Thus, both CRP and BP seem to be independent determinants of cardiovascular risk, and, in combination, each parameter may have additional predictive value ([@b10]; [@b15]; [@b8]).

CRP may be more than an inflammatory biomarker of increased cardiovascular risk, as deposits of CRP have been demonstrated by immunohistochemical staining in atherosclerotic plaques ([Figure 2](#fig2){ref-type="fig"}), where it co-localizes with the terminal complement complex and appears to be involved in foam cell formation ([@b73]). CRP promotes monocyte chemotaxis ([@b93]) and facilitates low-density lipoprotein uptake by macrophages in vitro ([@b93]). In endothelial cells, CRP facilitated the release of PAI-1 ([@b14]) and endothelin-1 ([@b83]), and increased the expression of cell adhesion molecules ([@b47]), reduced NO bioavailability ([@b82]), and NO-mediated dilation in the vasculature. In particular, CRP inhibited endothelium-dependent NO-mediated dilatation of coronary arterioles by inducing the generation of superoxide by NAD(P)H oxidase via p38 kinase activation ([@b52]). On the other hand, it has been reported that CRP per se does not activate endothelial cells. The latter has been attributed to contamination of CRP preparations with azide and lipopolysaccharide, which could be responsible for the cell activation ([@b71]). In VSMCs, CRP increased angiotensin type 1 receptor number and ROS formation ([@b86]), as well as activation of the stress-activated protein kinases p38 and c-jun N-terminal kinase (JNK) ([@b23]). It was recently reported that CRP caused a sustained increase in systolic BP in mice, related to an augmented pressor response to angiotensin II that is associated with a NO-sensitive downregulation of vascular angiotensin type 2 receptor expression ([@b85]).
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Along with the evidence that CRP is a marker and a modulator of inflammation, it has also been shown that CRP may possess anti-inflammatory actions. CRP inhibited neutrophil activation and adhesion ([@b25]; [@b91]) and blocked platelet aggregation in vitro ([@b17]; [@b84]; [@b42]). Accordingly, it has been proposed that distinct isoforms of CRP are formed during inflammation. CRP could dissociate into individual subunits that undergo conformational changes. The resulting monomeric CRP isoforms, express several neoepitopes and display properties distinct from those of native CRP ([@b50]; [@b92]; [@b30]). Monomeric CRP is less soluble than pentameric CRP, it tends to aggregate, and induces a pro-inflammatory phenotype in human endothelial cells ([@b31]). Monomeric CRP antigens were detected in inflammed tissues and in the wall of normal human blood vessels, and displayed potent pro-thrombotic activity under low levels of shear. In contrast, native CRP inhibited platetelet activation and prevented neutrophil--endothelial-cell and neutrophil--platelet adhesion. Hence monomeric CRP rather than native CRP may be involved in the precipitation of acute coronary syndrome ([@b32]).

Thus, CRP may be a pro-inflammatory molecule under certain circumstances, as well as a marker to consider in medium-risk cardiovascular patients.

Reducing vascular inflammation via antagonism of the RAS
========================================================

Arterial BP control is critical to reduce the burden of cardiovascular morbidity and mortality. Indeed, arterial hypertension contributes to increase the latter in combination with other cardiovascular risk factors (such as obesity, diabetes and dyslipidemia). JNC-VII and WHO-ISH and other national and international guidelines have suggested different non-pharmacological and pharmacological approaches to reduce BP in hypertensive patients ([@b11]; [@b87]). Since hypertension is a pro-inflammatory condition, non-pharmacological (weight loss, exercise and Mediterranean-style diet) and pharmacological therapeutic intervention to control BP have also been proposed to reduce vascular inflammation in patients with hypertension, in order to achieve a reduction of cardiovascular events and improved outcomes in randomized clinical trials.

Several therapeutic approaches have been shown to reduce CRP in patients at high cardiovascular risk. Exercise training, together with weight loss, reduced hsCRP levels significantly, although not in proportion to weight reduction ([@b45]). CRP decrease was observed in the middle weight-reduction quartile, suggesting that there may be an optimal link between exercise and weight loss with respect to the inflammatory status ([@b45]). Patients consuming a Mediterranean-style diet had a significant reduction in serum concentrations of hsCRP, IL-6, IL-7, and IL-18, as well as in insulin resistance ([@b16]).

In patients with high LDL-cholesterol levels, those with low hsCRP have better clinical outcomes than those with higher levels ([@b44]; [@b56]). Fenofibrate lowered hsCRP levels in patients with hypertriglyceridemia or combined hyperlipidemia ([@b36]). Statin-induced reduction of atherosclerosis progression was significantly related to greater reduction of hsCRP levels. Simvastatin or atorvastatin induced a reduction of CRP in coronary patients with hyperlipidemia ([@b69]). In patients with diabetes and hypercholesterolemia, simvastatin combined with the angiotensin converting enzyme (ACE) inhibitor ramipril significantly reduced CRP levels more than monotherapy ([@b37]).

In hypertensive patients in the presence or absence of diabetes, BP control with ACE inhibitors, angiotensin receptor blockers (ARBs), and calcium channel blockers was associated with a reduction in the circulating levels of inflammatory mediators ([@b20]; [@b59]; [@b2], [@b1]). Several lines of evidence suggest that the improvement in systemic and vascular inflammatory status observed in patients treated with antihypertensive medications might involve BP-independent actions, which have been attributed in part to direct inhibition of pro-inflammatory effects of angiotensin II ([@b34]; [@b65]). However, not all studies have demonstrated anti-inflammatory effects of agents that interrupt RAS. There is evidence that drugs that selectively block angiotensin II receptors or ACE may have superior anti-inflammatory properties than other antihypertensive agents. In subjects with uncomplicated hypertension, ACE inhibitors but not ARBs decreased plasma levels of adhesion molecules (VCAM-1, ICAM-1, E-selectin) ([@b26]). In older patients, ARBs reduced circulating levels of VCAM-1 but not of E-selectin ([@b53]). In diabetic nephropathy, ARBs decreased plasma adhesion molecules ([@b4]). In type 2 diabetic patients, ARBs diminished VCAM-1, whereas ACE inhibitors reduced ICAM-1 ([@b22]). We recently reported that antihypertensive treatment with an ARB ameliorated inflammatory processes and markedly reduced circulating pro-inflammatory mediators in diabetic hypertensive patients, independently by BP or glycemic control ([@b75]). Furthermore, CRP-induced up-regulation of the angiotensin type 1 receptor was attenuated by losartan ([@b86]). In another study in hypertensive patients, although MCP-1 and PAI-1 were variably reduced, losartan, irbesartan, or candesartan did not significantly reduce serum CRP ([@b35]). Also, whereas three small randomized clinical trials in patients with hypertension and cardiovascular disease showed a significant CRP-lowering effect by an ARB ([@b89]; [@b18]; [@b62]), in another study in hypertensive and diabetic patients no lowering of CRP could be detected ([@b2]).

Recently, the Val-MARC (Valsartan-Managing blood pressure Aggressively and evaluating Reductions in hsCRP) study, addressed the issue of whether BP reduction per se lowers CRP levels, or whether selective antagonism of angiotensin type 1 receptors may have independent effects to reduce CRP levels ([@b58]). The study included 1668 patients with stage 2 hypertension randomly allocated to either the ARB valsartan alone (160--320 mg/day) or to valsartan/hydrochlorothiazide (HCTZ, 160--320 mg/12.5 mg/day) for a period of 6 weeks. At the end of the treatment, valsartan alone slightly but significantly reduced hsCRP levels, effect that was maintained over an extended follow-up period. In contrast the combination therapy did not reduce CRP levels. The difference between valsartan and valsartan/HCTZ was present in all subgroups evaluated despite the fact that BP reduction was greater in the combined therapy group. Minimal evidence of correlation between change in BP and change in hsCRP was observed. Interestingly, CRP reduction associated with valsartan treatment was observed not only in the total cohort but also among the subjects taking statins, a class of agents that has been shown to significantly reduce hsCRP levels ([@b69]; [@b3]; [@b37]; [@b56]). Thus, these data support the hypothesis that ARBs may have anti-inflammatory effects independently of the degree of BP reduction. However, the implication of the very small change in CRP found with valsartan vs valsartan plus HCTZ remains unclear, as does the therapeutic importance of this difference, since in the clinic, most patients who receive an ARB also receive a thiazide diuretic. Nevertheless, these findings have recently been confirmed by a study performed in a large multiethnic cohort of patients receiving pharmacologic treatment for hypertension in which the use of ACE inhibitors and ARBs as monotherapy was associated with lower CRP levels ([@b46]).

Observational studies in patients with cardiovascular disease have also suggested that ARBs and ACE inhibitors lower serum CRP. In patients with ischemic heart disease undergoing heart catheterization, lower serum levels of CRP were observed when the patients were treated with an ARB ([@b70]). After coronary artery bypass surgery, patients who had received ACE inhibitors had lower levels of IL-6, the main modulator of CRP release by the liver ([@b9]). Moreover, ACE inhibitor use was associated with lower CRP levels in patients with heart failure ([@b27]). In the Val-Heft study, patients with congestive heart failure randomized to treatment with the ARB valsartan had lower hsCRP levels, whereas placebo-treated subjects did not ([@b5]).

Conclusion
==========

Hypertension may be considered a disease associated with low-grade inflammation that contributes to cardiovascular disease. Non pharmacological and pharmacological approaches to control high BP may decrease vascular inflammation independently of BP reduction in patients with hypertension, resulting in reduced cardiovascular events in randomized clinical trials. Among other antihypertensive agents, ARBs have shown more potent anti-inflammatory properties unrelated to BP-lowering effect of this class of drugs, but more probably the result of a direct antagonism of the pro-inflammatory effects induced by angiotensin II. Thus, although reducing BP is the primary goal in order to decrease cardiovascular events in hypertensive patients, reduction of low-grade inflammation in hypertension may be an interesting and important target in order to reduce the cardiovascular morbidity and mortality associated with hypertension.
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